<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201212082887N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-08-29</date_registration>
      <primary_sponsor>Vice chancellor for research, Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effects of  high dose of selenium in the treatment of patient with severe sepsis</public_title>
      <acronym></acronym>
      <scientific_title>The effect of high dose of selenium in mortality of patient with severe sepsis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>51</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/2760</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Before the beginning of the study by software the numbers of patients are randomly divided into 2 groups. With the arrival of each patient the cards are open for patient that the groups of patient are diagnosed.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Severe sepsis.</hc_freetext>
      <i_freetext>Intervention 1: One the first day study, begining 2000 microgram selenium boluses (in 1 hour) then 1500 microgram selenium 24 hour infusion for 14 days in 50 milliliter sodium chloride solution. Intervention 2: The standard treatment for sepsis without prescription selenium.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Arezoo Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina Hospital, Emam Khomeini Street, Hasan abad Square, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>aarezoo24@gmail.com</email>
        <affiliation>Sina  Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arezoo Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sina Hospital, Emam Khomeini Street, Hasan abad Square, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 6634 8500</telephone>
        <email>Aarezoo24@gmail.com</email>
        <affiliation>Sina Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Patient with suspected or documented diagnosis of infection with at least one of these: White blood cell (WBC) in sterile regions, Perforated viscera; Radiologic evidence of pneumonia and infected sputum; High risk infection such as Cholangitis; and at least three of the following: Body temperature above 38 degrees Celsius or under 36; Heart rate greater than 90 beat per minute without consuming any medication, Respiratory rate more than 20 per minute or arterial pressure of carbon dioxide less than 32 millimeter of mercury with mechanical ventilation; White blood cells more than 12000 or less than 1000; more than 10 percent band Neutrophils.&#13;
Exclusion criteria: more than 24 hours of diagnosis of sever sepsis; high probability death due to a nonspecific cause (renal insufficiency, hepatic encephalopathy, etc) within the first 28 days; pregnancy or lactating; Age less than 16 years; dissatisfaction of patient or his family to enter the study; patients with Cancer</inclusion_criteria>
      <agemin>17 years</agemin>
      <agemax>90 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>R65.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Systemic Inflammatory Response Syndrome of infectious origin with organ failure Severe sepsis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>One the first day study, begining 2000 microgram selenium boluses (in 1 hour) then 1500 microgram selenium 24 hour infusion for 14 days in 50 milliliter sodium chloride solution.</i_keyword>
      <i_keyword>The standard treatment for sepsis without prescription selenium</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mortality. Timepoint: Mortality within 28 days of after diagnosis with severe sepsis. Method of measurement: Counting the  number of patient died.</prim_outcome>
      <prim_outcome>Length of ICU stay. Timepoint: Number of bed days in ICU since entry into the research. Method of measurement: Registration for beding in ICU.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Level of Super Oxide Dismutase. Timepoint: Base line  and day 3, 7, 10, 14 after prescription. Method of measurement: measuring  enzyme concentration  in the blood.</sec_outcome>
      <sec_outcome>MMP (Matrix Metalloproteinase). Timepoint: Baseline and day 3, 7, 10, 14 after treatment with selenium. Method of measurement: measuring the enzyme concentration in the blood.</sec_outcome>
      <sec_outcome>PAF (Platelet-activating factor). Timepoint: Baseline and day 3, 7, 10, 14 days after treatments with selenium. Method of measurement: measuring  the concentration of PAF in the blood.</sec_outcome>
      <sec_outcome>Total anti oxidant power. Timepoint: Baseline and day 3, 7, 10, 14 after treatments with selenium. Method of measurement: measuring Anti-oxidant power concentration in the blood.</sec_outcome>
      <sec_outcome>Interleukin 1. Timepoint: Baseline and day 3, 7, 10, 14 after treatments with selenium. Method of measurement: measuring IL-1 concentration in the blood.</sec_outcome>
      <sec_outcome>TGF (Transforming Growth Factor). Timepoint: Baseline and day 3, 7, 10, 14 after treatment with selenium. Method of measurement: measuring TGF concentration in the blood.</sec_outcome>
      <sec_outcome>SOFA Score (Simplified Acute Physiology Score). Timepoint: Baseline and day 3, 7, 10, 14 after treatments with selenium. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>APACHI II Score (Acute Physiology and Chronic Health Evaluation II). Timepoint: Baseline and day 3, 7, 10, 14 after treatment with selenium. Method of measurement: Calculation.</sec_outcome>
      <sec_outcome>NGAL (Neutrophil Gelatinase Associated Lipocalin). Timepoint: Baseline and day 3, 7, 10, 14 after treatment with selenium. Method of measurement: measuring NGAL concentration in the blood.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-06-19</approval_date>
        <contact_name>Research center of Science Tehran University of Medical sciences</contact_name>
        <contact_address>Old building's School of Pharmacy, Tehran University of Medical Sciences Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
